Maternally-derived neutralizing antibodies reduce vaccine efficacy against porcine reproductive and respiratory syndrome virus infection.
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Biomarkers
Immunity, Maternally-Acquired
Immunization Schedule
Immunogenicity, Vaccine
Interferon-alpha
/ blood
Neutralization Tests
Porcine Reproductive and Respiratory Syndrome
/ immunology
Porcine respiratory and reproductive syndrome virus
/ immunology
Swine
Vaccination
/ veterinary
Vaccines, Attenuated
/ immunology
Viral Vaccines
/ immunology
IFNa
Interference
Maternally derived antibody
Modified live virus vaccine
Neutralizing antibody
PRRS virus
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
18 07 2019
18 07 2019
Historique:
received:
01
02
2019
revised:
12
06
2019
accepted:
14
06
2019
pubmed:
30
6
2019
medline:
20
9
2020
entrez:
29
6
2019
Statut:
ppublish
Résumé
Modified live virus (MLV) vaccines are commonly used to reduce the impact of porcine reproductive and respiratory syndrome (PRRS) but limited efficacy is achieved in field conditions. Here, we evaluated the impact of maternally-derived neutralizing antibodies (MDNAs) on vaccine efficacy after PRRS virus (PRRSV) challenge. Piglets with low (A-) or high (A+) MDNA levels derived from a commercial pig herd were moved to experimental facilities to be vaccinated (V+) or not (V-) with a PRRSV-1 MLV vaccine at 3 weeks of age (woa). Because of unexpectedly low vaccine detection in A-V+ piglets post-vaccination (pv), all V+ piglets received a second vaccination at 4 woa. Five weeks (W5) pv, piglets were inoculated with a PRRSV-1 field strain to evaluate vaccine protection, and were mingled 24 h later with non-inoculated piglets of similar immune status to assess viral transmission. Vaccine strain was detected at W2 pv in 69% and 6% of A-V+ and A+V+ piglets, and at W5 pv in 50% and 25% of A-V+ and A+V+ piglets, respectively. At W5 pv, 94% of A-V+ and 44% of A+V+ piglets seroconverted, with a significant IFNg response induction in the A-V+ group only. After challenge, compared to the V- inoculated group, viremia was 100-fold lower at 10 days post-infection in A-V+ whereas viremia was not significantly reduced in A+V+ piglets. A lower transmission rate was estimated for the A-V+ group: 0.15 [0.07-0.29] versus 0.44 [0.18-1.76] and 0.32 [0.14-0.68] for the A+V+ and V- groups, respectively. Investigations about the low vaccine strain detection after the first vaccination suggested a relationship between IFNa levels and vaccine strain detection in A-V+ piglets. We showed that MDNAs impair vaccine efficacy against PRRSV both in inoculated and contact piglets, probably by reducing vaccine replication. IFNa may also interfere with PRRSV vaccination. These new data could help improving vaccination protocols.
Identifiants
pubmed: 31248683
pii: S0264-410X(19)30807-2
doi: 10.1016/j.vaccine.2019.06.045
pmc: PMC7115427
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Biomarkers
0
Interferon-alpha
0
Vaccines, Attenuated
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4318-4324Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Vet Immunol Immunopathol. 2006 Dec 15;114(3-4):224-37
pubmed: 16978709
Vet J. 2008 Mar;175(3):356-63
pubmed: 17560818
Clin Vaccine Immunol. 2007 Mar;14(3):269-75
pubmed: 17215336
Virus Res. 2010 Dec;154(1-2):86-97
pubmed: 20692304
Infect Immun. 1981 Apr;32(1):28-31
pubmed: 6163724
Vet Immunol Immunopathol. 2015 Sep 15;167(1-2):1-14
pubmed: 26209116
J Am Vet Med Assoc. 2005 Aug 1;227(3):385-92
pubmed: 16121604
Vet Microbiol. 2005 Dec 20;111(3-4):151-7
pubmed: 16280205
Vaccine. 2016 Jun 8;34(27):3044-3050
pubmed: 27155497
Vet Microbiol. 2013 Dec 27;167(3-4):260-71
pubmed: 24041768
Am J Vet Res. 2001 Nov;62(11):1805-11
pubmed: 11703028
Virology. 2015 Sep;483:284-90
pubmed: 26004252
Vet Microbiol. 2016 Aug 30;192:175-180
pubmed: 27527780
Vet Microbiol. 2012 May 25;157(1-2):152-63
pubmed: 22226820
Vet Microbiol. 2017 Dec;212:48-51
pubmed: 29173587
Porcine Health Manag. 2016 Aug 14;2:24
pubmed: 28405450
Porcine Health Manag. 2018 Nov 15;4:25
pubmed: 30459958
Vaccine. 2011 Oct 26;29(46):8192-204
pubmed: 21925560
Ann N Y Acad Sci. 2006 Oct;1081:130-6
pubmed: 17135502
Vaccine. 2015 May 15;33(21):2493-9
pubmed: 25820061
Vaccine. 2009 Jun 8;27(28):3788-99
pubmed: 19442420
Vet J. 2011 Jan;187(1):48-53
pubmed: 20097110
Prev Vet Med. 2017 Jul 1;142:16-29
pubmed: 28606362
Vet Microbiol. 2018 Feb;214:113-124
pubmed: 29408022
Vet Microbiol. 2015 Jan 30;175(1):7-16
pubmed: 25439650